You are here
Exagen Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
Leader in rheumatology testing to present at investor conference in November
Albuquerque, NM and San Diego, CA, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics, a leader in autoimmune life sciences, today announced that President and Chief Executive Officer, Ron Rocca, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum to be held in New York, NY at the Westin Grand Central Hotel on Thursday, November 15, 2018 at 11:30 a.m. Eastern Time. Mr. Rocca will present an overview of the patented cell-bound complement activation products (CB-CAPs) technology and other recent advances for the AVISE® brand of testing.
Exagen is a commercial stage life sciences company that is patient focused, and discovery driven. Exagen serves patients and healthcare providers across the U.S. in the diagnosis, prognosis, and management of lupus, rheumatoid arthritis, and other autoimmune conditions. By leveraging our patented and validated CB-CAPs technology we can help get to the real cause of a patient’s symptoms and guide their journey to improved health. For more information, visit exagen.com or follow us on Facebook, Twitter, YouTube, LinkedIn, or Instagram.
CONTACT: Kamal Adawi Exagen Diagnostics, Inc. 760.477.5514 IR@exagen.com